Skip to main content

Table 1 Case reports of SLE during pregnancy with uterine wall thinning and PAS

From: Diffuse myometrium thinning and placenta accreta spectrum in a patient with systemic lupus erythematosus (SLE): a case report and review of the literature

Author,year Age(y) Parity PSL duration(y) PSL use during pregnancy Risk factors of PAS Obstetric complication GA at labror(wk) Induction labor Delivery Treatment Amount of blood loss(ml)
Noh JJ et al., 2013 [2] 36 0 19 Yes IVF Rupture uterus 23 None CS Hysterectomy NS
Tokushige Y et al., 2017 [3] 35 0 5 Yes IVF GH 39 Yes (Oxytocin) CS Hysterectomy 4500
Tomimatsu T et al., 2021 [4] 32 0 8 Yes IVF PE 35 Yes (Oxytocin) CS Hysterectomy 2200
Mittal N et al., 2018 [5] 36 2 9 Yes Placenta previa Placenta previa 36 None CS Hysterectomy 6000
Kim HM et al., 2020 [6] 33 0 10 Yes None Rupture uterus 34 None CS Hysterectomy NS
Kim HM et al., 2020 [6] 30 0 8 NS None None 38 None CS Hysterectomy NS
Inoue A et al., 2020 [7] 37 0 19 Yes IVF NRFS,FGR 36 None CS Hysterectomy 5860
Our case 29 0 2 none none none 39 Yes (Oxytocin) CS Hysterectomy 5400
  1. Abbreviations: PSL predonisolone;GA,gestational age, IVF in vitro fertilization, CS cesarean section, GH gestational hypertension, PE preeclampsia, NRFS non-reassuring fetal status, FGR fetal growth restriction, NS not stated, SLE systemic lupus erythematosus, PAS placenta accrete spectrum